212 related articles for article (PubMed ID: 30303022)
21. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
[TBL] [Abstract][Full Text] [Related]
22. Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.
Yu TY; Dai MS
J Hematol; 2020 Apr; 9(1-2):30-32. PubMed ID: 32362983
[TBL] [Abstract][Full Text] [Related]
23. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Hux M; Zou D; Ma E; Sajosi P; Engstrom A; Selby R; Benson E; Briggs A; Bonthapally V
J Health Econ Outcomes Res; 2017; 4(2):188-203. PubMed ID: 37661948
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
27. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
30. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.
Lai Y; Bensimon AG; Gao E; Bhattacharya R; Xu R; Chevure J; Imai K; Haas NB
Clin Genitourin Cancer; 2023 Oct; 21(5):612.e1-612.e11. PubMed ID: 37137809
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
40. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]